|
Method for Identifying and Optimizing the Development of Heterodimeric Monoclonal Antibodies
Application
Method to generate IgG heterodimers that can be used to generate bi-specific monoclonal antibodies for disease treatment.
Key Benefits
A novel method of screening and developing novel IgG heterodimers used for generating monoclonal antibodies for many diseases.
Preliminary data demonstrate efficient production of IgG heterodimers that...
Published: 4/23/2024
Contributor(s): Eric Sundberg, Jonathan Du, Tala Azzam
|
|
Engineering Asymmetrically Glycosylated IgG Antibodies
Application
A novel method to develop asymmetrically glycosylated therapeutic monoclonal IgG antibodies for preventing and treating diseases like cancer, infectious diseases, and autoimmune disorders.
Key Benefits
Different IgG antibody glycoforms can be produced, each with its unique effector functions and biological and therapeutic effects.
Potential...
Published: 4/23/2024
Contributor(s): Eric Sundberg, Jonathan Du, Tala Azzam
|
|
SARS-CoV-2 Neutralizing Human Monoclonal Antibodies
Application
Monoclonal antibodies to SARS-CoV2 for use in COVID-19 diagnostics and therapeutics.
Key Benefits
Demonstrably neutralizing, important for therapeutic mAbs.
Most bind both RBG and stalk portion of spike protein, useful in case SARS-CoV2 strains develop variation in RBD.
Market Summary
Coronavirus (COVID-19) is an infectious...
Published: 4/23/2024
Contributor(s): Jens Wrammert, Carl Davis, Mehul Suthar, Robert Kauffman
|
|
BG505 SOSIP Vaccine Elicited Neutralizing Monoclonal Antibodies for HIV
Application
ELISA
Western Blot
Immunohistochemistry
Specficity
HIV-1 BG505 Env protein (clone name: YRK01, YRK02).
Subtype
Monoclonal antibody.
Immunogen
HIV-1 BG505 SOSIP Env trimer.
Technical Summary
HIV-1 envelope glycoprotein (Env) is a membrane protein complex involved in receptor recognition and viral fusion with CD4+ T cells...
Published: 3/1/2024
Contributor(s): Cynthia Derdeyn, Tysheena Charles
|
|
Using Antibodies to Inhibit Glycoprotein Ib-IX Mediated Platelet Signaling and Clearance for the Treatment of Thrombocytopenia
Application
A therapeutic agent to treat thrombocytopenia, the lack of sufficient platelets which can lead to excessive bleeding.
Key Benefits
This molecule modulates platelet signaling without blocking its ligand binding domain. Its mechanism of action targets a different part of the platelet life cycle from currently available therapeutics.
RAM.1...
Published: 11/27/2023
Contributor(s): Renhao Li, Francois Lanza, Wenchun Chen, Moriah Wilson
|
|
Additives that Increase Storage and Shelf Life of Platelets
Application
Monoclonal antibody additive that inhibits ectodomain shedding of a platelet glycoprotein to improve platelet storage.
Key Benefits
Current storage techniques allows for limited storage times (5-7 days).
New additive may enable platelet storage at 4°C, increase platelet storage time, and improve quality of stored platelets.
Inhibits...
Published: 4/23/2024
Contributor(s): Renhao Li
|
|
Galectin-9 Directed CAR T-cells for Overcoming Resistance to Chemotherapy in Hematological Malignancies
Application
Anti-human Galectin-9-directed chimeric antigen receptor (CAR) T-cells for treatment of hematological malignancies (B-ALL, T-ALL, and DLBCL) in normal, overweight, and obese patients.
Key Benefits
Can be used as a stand-alone or in-combination product to treat patients with hematological malignancies, particularly overweight and obese...
Published: 4/23/2024
Contributor(s): Curtis Henry, Miyoung (Mi-Young) Lee, Sunil Raikar, Jamie Hamilton, Anthony Ross
|
|
Trimeric Immunogen for HIV-1 Vaccination
Application
Trimeric gp120 immunogen that induces broadly cross-reactive V1V2-antibodies for HIV-1 vaccine.
Key Benefits
Possible oral administration.
Broadly cross-reactive against HIV-1 panel.
Promotes antibody responses as both a primary immunogen and boosting immunogen.
Market Summary
Antiretroviral therapy (ART) has dramatically prolonged...
Published: 4/23/2024
Contributor(s): Rama Rao Amara, Andrew Jones, Raghavan Varadarajan, Sannula Kesavardhana
|
|
Antibody Therapy for Varicella Zoster Virus
Application
Human monoclonal antibodies for the treatment of varicella zoster virus (VZV).
Key Benefits
Human monoclonal antibodies can limit the spread of VZV.
gH-specific antibodies are complement-independent.
Market Summary
Varicella Zoster Virus (VZV) causes varicella, more commonly known as chickenpox. Once the illness resolves, the virus...
Published: 4/23/2024
Contributor(s): Rafi Ahmed, Nicole Sullivan
|
|
Antibodies for Zika and Dengue Viruses
Applications
ELISA
Western Blot
Immunohistochemistry
Specificity
Human monoclonal
Technical Summary
Zika Virus (ZIKV) is a mosquito borne filovirus responsible for a 2016-2017 epidemic in North and South America. ZIKV nonstructural protein 1 (NS1) is a pathogenicity factor implicated in virus replication, host interaction and immune invasion....
Published: 4/23/2024
Contributor(s): Jens Wrammert, Mark Mulligan
|